Adriano Lazzarin

机构：Vita-Salute San Raffaele University · ORCID：0000-0003-2551-7754

发表论文 1006 篇 · 总被引 33187 次 · h-index 87

代表论文

• Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials (2023 · EClinicalMedicine · 被引 90)
• Biobanking for COVID-19 research (2021 · Panminerva Medica · 被引 52)
• Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study (2023 · Clinical Infectious Diseases · 被引 23)
• Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy (2024 · AIDS · 被引 18)
• Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort (2025 · Journal of Antimicrobial Chemotherapy · 被引 15)
• Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort (2024 · Journal of Antimicrobial Chemotherapy · 被引 10)